SYLVANT® (siltuximab) is the only FDA-approved treatment for idiopathic multicentric Castleman disease (iMCD)*

Learn More
*SYLVANT is an interleukin-6 (IL-6) antagonist indicated for the treatment of patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.

SYLVANT® (siltuximab):
Anti–IL‑6 treatment to help neutralize a cytokine storm

How SYLVANT Works

Clinical
Presentation
of iMCD

Learn More

How
SYLVANT
Works

Watch MOA Video

Diagnosing
iMCD

Learn More

Dosing and
Administration

Administering SYLVANT

Patient Connect
Can Help

Learn About Patient Services

Contact
a Rep

Get in Touch
Abbreviations: FDA, US Food and Drug Administration; IL-6, interleukin-6.